Actinium Pharmaceuticals
ATNM
42 hedge funds and large institutions have $7.05M invested in Actinium Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 8 closing their positions.
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
17% more funds holding
Funds holding: 36 → 42 (+6)
0.35% less ownership
Funds ownership: 0.68% → 0.33% (-0.35%)
14% less capital invested
Capital invested by funds: $8.22M → $7.05M (-$1.17M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$211K |
| 2 |
Renaissance Technologies
New York
|
+$152K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$51.2K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$50.9K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$37.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.23M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$1.5M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$729K |
| 4 |
DAM
DLD Asset Management
New York
|
-$106K |
| 5 |
SCM
Sio Capital Management
New York
|
-$86.1K |
ATNM Hedge Fund Activity: Q2 2018 in Review
42 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2018, worth a combined $7.05M — down 14% from $8.22M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ATNM positions and 8 closed out — a net gain of 6 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Credit Suisse, adding an estimated $211K. The largest seller was Armistice Capital, exiting entirely with an estimated $2.23M sold.
- 42 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2018, up from 36 in Q1 2018.
- Funds reported $7.05M of Actinium Pharmaceuticals stock for Q2 2018, down 14% quarter-over-quarter.
- 14 funds opened new Actinium Pharmaceuticals positions in Q2 2018 and 8 closed out, a net change of +6 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2018 was Credit Suisse, an estimated $211K added.
- The largest Actinium Pharmaceuticals seller in Q2 2018 was Armistice Capital, an estimated $2.23M sold.
Based on aggregated 13F filings for Q2 2018.